DE122005000011I1 - Verwendung von Tomoxet in zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsstörungen. - Google Patents

Verwendung von Tomoxet in zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsstörungen.

Info

Publication number
DE122005000011I1
DE122005000011I1 DE200512000011 DE122005000011C DE122005000011I1 DE 122005000011 I1 DE122005000011 I1 DE 122005000011I1 DE 200512000011 DE200512000011 DE 200512000011 DE 122005000011 C DE122005000011 C DE 122005000011C DE 122005000011 I1 DE122005000011 I1 DE 122005000011I1
Authority
DE
Germany
Prior art keywords
hyperactivity
tomoxet
treatment
attention deficit
deficit disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE200512000011
Other languages
English (en)
Other versions
DE122005000011I2 (de
Inventor
John Harrison Heiligenstein
Gary Dennis Tollefson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23463572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122005000011(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE122005000011I1 publication Critical patent/DE122005000011I1/de
Publication of DE122005000011I2 publication Critical patent/DE122005000011I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
DE200512000011 1995-01-11 1996-01-09 Verwendung von Tomoxetin zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsst¦rungen Active DE122005000011I2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/371,341 US5658590A (en) 1995-01-11 1995-01-11 Treatment of attention-deficit/hyperactivity disorder

Publications (2)

Publication Number Publication Date
DE122005000011I1 true DE122005000011I1 (de) 2005-06-23
DE122005000011I2 DE122005000011I2 (de) 2006-02-09

Family

ID=23463572

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69623141T Expired - Lifetime DE69623141T2 (de) 1995-01-11 1996-01-09 Verwendung von Tomoxetin zur Behandlung von Hyperaktivität mit Aufmerksamkeitsstörungen
DE200512000011 Active DE122005000011I2 (de) 1995-01-11 1996-01-09 Verwendung von Tomoxetin zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsst¦rungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69623141T Expired - Lifetime DE69623141T2 (de) 1995-01-11 1996-01-09 Verwendung von Tomoxetin zur Behandlung von Hyperaktivität mit Aufmerksamkeitsstörungen

Country Status (28)

Country Link
US (1) US5658590A (de)
EP (1) EP0721777B1 (de)
JP (2) JPH10512262A (de)
KR (1) KR19980701276A (de)
CN (2) CN1781480A (de)
AT (1) ATE222757T1 (de)
AU (1) AU688665B2 (de)
BR (1) BR9606903A (de)
CA (1) CA2209735C (de)
CZ (1) CZ292226B6 (de)
DE (2) DE69623141T2 (de)
DK (1) DK0721777T3 (de)
ES (1) ES2181845T3 (de)
FI (1) FI119354B (de)
FR (1) FR10C0041I2 (de)
HU (1) HU227306B1 (de)
LU (1) LU91238I2 (de)
NL (1) NL300180I2 (de)
NO (1) NO317027B1 (de)
NZ (1) NZ301500A (de)
PL (1) PL187573B1 (de)
PT (1) PT721777E (de)
RO (1) RO118374B1 (de)
RU (1) RU2163802C2 (de)
SI (1) SI0721777T1 (de)
TR (1) TR199700627T1 (de)
UA (1) UA43385C2 (de)
WO (1) WO1996021430A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
GB9613243D0 (en) * 1996-06-25 1996-08-28 Britannia Pharmaceuticals Ltd Attention deficit hyperactive disorder
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
CA2304112A1 (en) * 1997-09-23 1999-04-01 John Harrison Heiligenstein Treatment of attention-deficit/hyperactivity disorder
US5902797A (en) * 1997-11-10 1999-05-11 Beth Israel Deaconess Medical Center Nutritional supplement for use in the treatment of attention deficit
AU756373B2 (en) * 1998-04-09 2003-01-09 Pharmacia & Upjohn Company New treatments for nervous disorders
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
AU761844C (en) * 1998-11-09 2004-09-23 F. Hoffmann-La Roche Ag Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6898455B2 (en) * 1999-10-29 2005-05-24 The Mclean Hospital Corporation Method for providing optimal drug dosage
US6400978B1 (en) 1999-10-29 2002-06-04 The Mclean Hospital Corporation Method and apparatus for detecting mental disorders
DZ3282A1 (fr) * 2000-03-07 2001-09-13 Lilly Co Eli Traitement du psoriasis
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
PL369311A1 (en) * 2001-12-11 2005-04-18 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
ES2315525T3 (es) 2002-08-23 2009-04-01 Eli Lilly And Company Derivados de 2-(feniltiometil)-morfolina para uso como inhibidores selectivos de la recaptacion de norepinefrina.
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
WO2005011583A2 (en) * 2003-07-28 2005-02-10 Leslie Joe Dunaway Treatment of allergic rhinitis and asthma
EP1660064A2 (de) * 2003-08-27 2006-05-31 Eli Lilly And Company Behandlung von lernstörungen und motorischen störungen mit norepinephrin-wiederaufnahme-hemmern
US20060241188A1 (en) * 2003-08-27 2006-10-26 Elililly And Company Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors
US20050152974A1 (en) * 2003-12-31 2005-07-14 Garth Boehm Atomoxetine formulations
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US20070219201A1 (en) * 2004-05-27 2007-09-20 Warner-Lambert Company Llc Combination of atomoxetine and a 5ht1a receptor agonist for treating adhd and other disorders
CA2561386A1 (en) * 2004-06-28 2006-01-12 Teva Pharmaceutical Fine Chemicals S.R.L. Enantiomerically pure atomoxetine and tomoxetine mandelate
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
CA2568629A1 (en) 2004-07-22 2006-02-23 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
WO2006108120A1 (en) * 2005-04-05 2006-10-12 Teva Pharmaceutical Fine Chemicals S.R.L. Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1951643A1 (de) * 2005-11-23 2008-08-06 Auspex Pharmaceuticals Inc. Substituierte aryloxypropylamine mit serotoninergischer und/oder norepinephrinergischer aktivität
WO2007065655A1 (en) 2005-12-07 2007-06-14 Neurosearch Sweden Ab Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission
US20080020387A1 (en) * 2006-03-31 2008-01-24 Lawrence Donald G Biomarker-optimized adhd treatment
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
US20080031932A1 (en) * 2006-08-04 2008-02-07 Watson Laboratories, Inc. Transdermal atomoxetine formulations and associated methods
US20080145318A1 (en) * 2006-12-13 2008-06-19 Midha Kamal K Atomoxetine formulations and associated methods
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
US20100069390A1 (en) * 2008-09-05 2010-03-18 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
RU2395313C2 (ru) * 2008-10-15 2010-07-27 Татьяна Прохоровна Тетерина Способ коррекции синдрома дефицита внимания и гиперактивности
NZ600256A (en) 2009-12-02 2014-05-30 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
EP4011364B1 (de) 2011-03-23 2023-12-13 Ironshore Pharmaceuticals & Development, Inc. Verfahren und zusammensetzungen zur behandlung von aufmerksamkeitsdefizitsyndrom
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
WO2013119794A1 (en) 2012-02-08 2013-08-15 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
DK2838510T3 (en) 2013-11-08 2016-12-19 Lilly Co Eli Atomoxetine solution
CA2936740C (en) 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457121A (en) * 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine

Also Published As

Publication number Publication date
JP2005325139A (ja) 2005-11-24
LU91238I2 (fr) 2006-07-03
EP0721777A2 (de) 1996-07-17
US5658590A (en) 1997-08-19
HUP9801283A2 (hu) 1999-06-28
UA43385C2 (uk) 2001-12-17
DK0721777T3 (da) 2002-10-07
AU4693896A (en) 1996-07-31
JPH10512262A (ja) 1998-11-24
FR10C0041I1 (de) 2010-10-15
NZ301500A (en) 2000-07-28
SI0721777T1 (en) 2003-02-28
PL187573B1 (pl) 2004-08-31
AU688665B2 (en) 1998-03-12
CA2209735C (en) 2002-10-01
RU2163802C2 (ru) 2001-03-10
HU227306B1 (en) 2011-03-28
NO973170D0 (no) 1997-07-08
EP0721777A3 (de) 1997-03-05
DE122005000011I2 (de) 2006-02-09
PT721777E (pt) 2002-11-29
CA2209735A1 (en) 1996-07-18
DE69623141D1 (de) 2002-10-02
EP0721777B1 (de) 2002-08-28
CN1168095A (zh) 1997-12-17
RO118374B1 (ro) 2003-05-30
WO1996021430A1 (en) 1996-07-18
KR19980701276A (ko) 1998-05-15
NL300180I2 (nl) 2005-08-01
NO973170L (no) 1997-09-02
CN1781480A (zh) 2006-06-07
BR9606903A (pt) 1997-10-21
FI972922A0 (fi) 1997-07-09
CZ214597A3 (cs) 1998-01-14
ATE222757T1 (de) 2002-09-15
CZ292226B6 (cs) 2003-08-13
FI119354B (fi) 2008-10-31
HUP9801283A3 (en) 1999-09-28
FR10C0041I2 (de) 2011-04-29
NO317027B1 (no) 2004-07-26
ES2181845T3 (es) 2003-03-01
MX9705117A (es) 1997-10-31
PL321273A1 (en) 1997-11-24
FI972922A (fi) 1997-07-09
TR199700627T1 (xx) 1998-01-21
NL300180I1 (nl) 2005-05-02
DE69623141T2 (de) 2003-04-24

Similar Documents

Publication Publication Date Title
DE122005000011I1 (de) Verwendung von Tomoxet in zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsstörungen.
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
BR0010600A (pt) Método para inativação de cisto de giardia e cryptosporidium usando-se luz ultravioleta
RU97113060A (ru) Лечение синдрома дефицита внимания/гиперактивности
DE69528475T2 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
NZ313076A (en) Medicament containing duloxetine for treating hyperactivity and attention deficiency disorders
DE59202663D1 (de) Verwendung eines UV-Strahlers zur Behandlung von Oberflächen.
ATE95694T1 (de) Verwendung von bezafibrat zur behandlung von diabetes.
ATE142875T1 (de) Methode zur behandlung von haarausfall
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
ATE354361T1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
DE69711422T2 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
ATE367824T1 (de) Faktor xiii in kombination mit faktor ix zur behandlung von hämophilie b
DE50000676D1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis
ATE253945T1 (de) Verwendung von wundverbänden zur behandlung von akuten wunden
DE59901695D1 (de) Verfahren zur Herstellung von 2,4-Dichlor-3,5-dimethylfluorbenzol